Biofunctionalized targeted nanoparticles for therapeutic applications

Expert Opinion on Biological Therapy

Volumn 8, Issue 8, 2008, Pages 1063-1070

  Wang, Andrew Z ^a   Gu, Frank ^b   Zhang, Liangfang ^b   Chan, Juliana M ^b   Radovic Moreno, Aleksander ^b   Shaikh, Mariam R ^b   Farokhzad, Omid C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Biofunctionalized; Nanoparticle; Targeted nanoparticles; Targeting; Therapeutics delivery

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANGIOCEPT; ANTIBIOTIC AGENT; ASPARAGINASE MACROGOL; BEVACIZUMAB; CARBONYL IRON; CETUXIMAB; CILENGITIDE; CYANOACRYLATE DERIVATIVE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; LIPOSOME; MACROGOL; NANOPARTICLE; PAGSYS; PEGADEMASE; PEGAPTANIB; PEGINTERFERON ALPHA2A; PEGVISOMANT; POLYAMIDOAMINE; POLYCAPROLACTONE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYMER; POLYPROPYLENE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TRASTUZUMAB; UNINDEXED DRUG;

ACROMEGALY; ACUTE LYMPHOBLASTIC LEUKEMIA; BIOLOGICAL ACTIVITY; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DRUG BINDING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; EXPERIMENTAL STUDY; GENE TARGETING; HEPATITIS B; HEPATITIS C; HUMAN; HYDROPHOBICITY; IMMUNOGENICITY; LIPOSOMAL DELIVERY; LUNG NON SMALL CELL CANCER; MOLECULAR SIZE; NEUTROPENIA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PANCREAS CANCER; PROSTATE CANCER; RETINA MACULA DEGENERATION; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY;

DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; NANOPARTICLES; THERAPEUTICS;

EID: 47949120334     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.8.1063     Document Type: Review

References (67)

1. Wagner V, Dullaart A, Bock A-K, Zweck A. The emerging nanomedicine landscape. Nat Biotech 2006;24:1211-7
2. Emerich DF, Thanos CG. Targeted nanoparticle-based drug delivery and diagnosis. J Drug Target 2007;15(3):163-83
3. Groneberg DA, Giersig M, Welte T, Pison U. Nanoparticle-based diagnosis and therapy. Curr Drug Targets 2006;7(6):643-8
4. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002;94(l):25-36
5. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995;13(7):1777-85
6. Zhang L, Granick S. How to stabilize phospholipid liposome (using nanoparticles). Nano Lett 2006;6:694-8
7. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-59
8. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6:688-701
9. Tanaka T, Shiramoto S, Miyashita M, et al. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm 2004;277(l-2):39-61
10. Deguchi J-o, Aikawa M, Tung C-H, et al. Inflammation in atherosclerosis - visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006;114:55-62
11. Davis FE The origin of pegnology. Adv Drug Deliv Rev 2002;54(4):457-8
12. Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev 2005;57(15):2106-29
13. Bosman AW, Janssen HM, Meijer EW. About dendrimers: structure, physical properties, and applications. Chem Rev 1999;99(7):1665-88
14. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53(2):283-318
15. Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long-circulating polymeric nanospheres. Science 1994;263(5153):1600-3
16. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007;24:1-16
17. Tobio M, Gref R, Sanchez A, et al. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 1998;15(2):270-5
18. Perez C, Sanchez A, Putnam D, et al. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release 2001;75(l-2):211-24
19. Langer R. New methods of drug delivery. Science 1990;249(4976):1527-33
20. Langer R, Tirrell DA. Designing materials for biology and medicine. Nature 2004;428(6982):487-92
21. Edelman ER, Mathiowitz E, Langer R, Klagsbrun M. Controlled and modulated release of basic fibroblast growth factor. Biomaterials 1991;12(7):619-26
22. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature 1976;263(5580):797-800
23. Langer R. Drug delivery and targeting. Nature 1998;392(6679 Suppl):5-10
24. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006;103(16):6315-20
25. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002;82(2-3):189-212
26. Pandey R, Khuller GK. Nanotechnology based drug delivery system(s) for the management of tuberculosis. Indian J Exp Biol 2006;44(5):357-66
27. Hirsch LR, Gobin AM, Lowery AR, et al. Metal nanoshells. Ann Biomed Eng 2006;34(1):15-22
28. Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 2003;100(23):13549-54
29. Arias JL, Gallardo V, Linares-Molinero F, Delgado AV. Preparation and characterization of carbonyl iron/ poly(butylcyanoacrylate) core/shell nanoparticles. J Colloid Interface Sci 2006;299(2):599-607
30. Li Y, Tseng YD, Kwon SY, et al. Controlled assembly of dendrimer-like DNA. Nat Mater 2004;3(l):38-42
31. Khaled A, Guo S, Li F, Guo P Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett 2005;5(9):1797-808
32. Brennan FR, Shaw L, Wing MG, Robinson C. Preclinical safety testing of biotechnology-derived pharmaceuticals -understanding the issues and addressing the challenges. Mol Biotechnol 2004;27(l):59-74
33. Weinberg WC, Frazier-Jessen MR, Wu WJ, et al. Development and regulation of monoclonal antibody products: challenges and opportunities. Cancer Metastasis Rev 2005;24(4):569-84
34. Wilson DS, Szostak JW. In vitro selection of functional nucleic acids. Ann Rev Biochem 1999:68:611-47
35. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990;249(4968):505-10
36. Ellington AD, Szostak JW. Selection in vitro of single-stranded-DNA molecules that fold into specific ligand-binding structures. Nature 1992;355(6363):850-2
37. Green R, Ellington AD, Szostak JW. In vitro genetic-analysis of the Tetrahymena self-splicing intron. Nature 1990;347(6291):406-8
38. Schneider D, Tuerk C, Gold L. Selection of high-affinity RNA ligands to the bacteriophage-R17 coat protein. J Mol Biol 1992;228(3):862-9
39. Irvine D, Tuerk C, Gold L. Selexion -systematic evolution of ligands by exponential enrichment with integrated optimization by nonlinear-analysis. J Mol Biol 1991;222(3):739-61
40. Lee JF, Hesselberth JR, Meyers LA, Ellington AD. Aptamer database. Nucleic Acids Res 2004;32:D95-100
41. Lee JF, Stovall GM, Ellington AD. Aptamer therapeutics advance. Curr Opin Chem Biol 2006;10(3):282-9
42. Green LS, Jellinek D, Bell C, et al. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 1995;2(10):683-95
43. Ruckman J, Green LS, Beeson J, et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998;273(32):20556-67
44. Beekman KW, Colevas AD, Cooney K, et al. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer 2006;4(4):299-302
45. Gill DS, Damle NK. Biopharmaceutical drug discovery using novel protein scaffolds. Curr Opin Biotechnol 2006;17(6):653-8
46. Tschopp J, Mollnes TE. Antigenic crossreactivity of the α subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor. Proc Natl Acad Sci USA 1986;83(12):4223-7
47. Hansson M, Ringdahl J, Robert A, et al. An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein. Immunotechnology 1999;4(3-4):237-52
48. Steffen AC, Wikman M, Tolmachev V, et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm 2005;20(3):239-48
49. Hu S, Shively L, Raubitschek A, et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56(13):3055-61
50. Wu AM, Yazaki PJ. Designer genes: recombinant antibody fragments for biological imaging. QJ Nucl Med 2000;44(3):268-83
51. Cortez-Retamozo V, Backmann N, Senter PD, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 2004;64(8):2853-7
52. Qiu XQ, Wang H, Cai B, et al. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat Biotechnol 2007;25(8):921-9
53. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 2002;54(5):675-93
54. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84
55. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34
56. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23(15):3502-8
57. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235-42
58. Kim SH, Jeong JH, Chun KW, Park TG. Target-specific cellular uptake of PLGA nanoparticles coated with poly(I,-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir 2005;21(19):8852-7
59. Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004;64(21):7668-72
60. Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 2008;105(7):2586-91
61. Oyewumi MO, Yokel RA, Jay M, et al. Comparison of cell uptake, biodistribucion and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J Control Release 2004;95(3):613-26
62. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66(13):6732-40
63. Kukowska-Latallo JF, Candido KA, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005;65(12):5317-24
64. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8(4):1172-81
65. Bartlett DW, Su H, Hildebrandt IJ, et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 2007;104(39):15549-54
66. Matsumura Y, Gotoh M, Muro K, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 2004;15(3):517-25
67. Noble CO, Kirpotin DB, Hayes ME, et al. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 2004;8(4):335-53